Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

G. Curigliano; V. Mueller; V. Borges; E. Hamilton; S. Hurvitz; S. Loi; R. Murthy; A. Okines; E. Paplomata; D. Cameron; L.a. Carey; K. Gelmon; G.n. Hortobagyi; I. Krop; S. Loibl; M. Pegram; D. Slamon; J. Ramos; W. Feng; E. Winer

doi:10.1016/j.annonc.2021.12.005

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

G. Curigliano
, V. Mueller
, V. Borges
, E. Hamilton
, S. Hurvitz
, S. Loi
, R. Murthy
, A. Okines
, E. Paplomata
, D. Cameron
, L.a. Carey
, K. Gelmon
, G.n. Hortobagyi
, I. Krop
, S. Loibl
, M. Pegram
, D. Slamon
, J. Ramos
, W. Feng
, E. Winer

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	321-329
Journal	Annals of Oncology
Volume	33
Issue number	3
DOIs	https://doi.org/10.1016/j.annonc.2021.12.005
Publication status	Published - 22 Dec 2021

Access to Document

10.1016/j.annonc.2021.12.005Licence: CC BY-NC-ND

PIIS0923753421048791
0923-7534/© 2022 The Authors. Published by Elsevier Ltd on behalf of Eu-ropean Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Final published version, 449 KBLicence: CC BY-NC-ND

https://linkinghub.elsevier.com/retrieve/pii/S0923753421048791

Cite this

Curigliano, G., Mueller, V., Borges, V., Hamilton, E., Hurvitz, S., Loi, S., Murthy, R., Okines, A., Paplomata, E., Cameron, D., Carey, L. A., Gelmon, K., Hortobagyi, G. N., Krop, I., Loibl, S., Pegram, M., Slamon, D., Ramos, J., Feng, W., & Winer, E. (2021). Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Annals of Oncology, 33(3), 321-329. https://doi.org/10.1016/j.annonc.2021.12.005

@article{25157a319b8843f7a746f7a682234593,

title = "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis",

author = "G. Curigliano and V. Mueller and V. Borges and E. Hamilton and S. Hurvitz and S. Loi and R. Murthy and A. Okines and E. Paplomata and D. Cameron and L.a. Carey and K. Gelmon and G.n. Hortobagyi and I. Krop and S. Loibl and M. Pegram and D. Slamon and J. Ramos and W. Feng and E. Winer",

year = "2021",

month = dec,

day = "22",

doi = "10.1016/j.annonc.2021.12.005",

language = "English",

volume = "33",

pages = "321--329",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "3",

}

Curigliano, G, Mueller, V, Borges, V, Hamilton, E, Hurvitz, S, Loi, S, Murthy, R, Okines, A, Paplomata, E, Cameron, D, Carey, LA, Gelmon, K, Hortobagyi, GN, Krop, I, Loibl, S, Pegram, M, Slamon, D, Ramos, J, Feng, W & Winer, E 2021, 'Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis', Annals of Oncology, vol. 33, no. 3, pp. 321-329. https://doi.org/10.1016/j.annonc.2021.12.005

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. / Curigliano, G.; Mueller, V.; Borges, V. et al.
In: Annals of Oncology, Vol. 33, No. 3, 22.12.2021, p. 321-329.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

AU - Curigliano, G.

AU - Mueller, V.

AU - Borges, V.

AU - Hamilton, E.

AU - Hurvitz, S.

AU - Loi, S.

AU - Murthy, R.

AU - Okines, A.

AU - Paplomata, E.

AU - Cameron, D.

AU - Carey, L.a.

AU - Gelmon, K.

AU - Hortobagyi, G.n.

AU - Krop, I.

AU - Loibl, S.

AU - Pegram, M.

AU - Slamon, D.

AU - Ramos, J.

AU - Feng, W.

AU - Winer, E.

PY - 2021/12/22

Y1 - 2021/12/22

U2 - 10.1016/j.annonc.2021.12.005

DO - 10.1016/j.annonc.2021.12.005

M3 - Article

SN - 0923-7534

VL - 33

SP - 321

EP - 329

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -